Is COVID-19-Related Mucormycosis Now a Threat in Europe?

Year 2022, Volume: 5 Issue: 3, 102 - 104, 15.12.2022

Emel Tahir , Özgür Kemal , Mustafa Aktaş , Aynur Atilla

Abstract

The frequency of secondary infections has also increased following the ongoing coronavirus pandemic. We aimed to attract attention to the COVID-19-related mucormycosis, a highly mortal complication of COVID-19, and its treatment. A retrospective review of the patient database was performed after the pandemic declaration. These patients’ medical files, treatment charts, and radiological and histological data were examined. The study group consisted of three COVID-19-related mucormycosis patients. All three patients had uncontrolled diabetes. One patient had no previously diagnosed diabetes and died due to widespread mucor infection and severe ketoacidosis. In the other two patients, the diagnosis was made promptly by frozen examination, endoscopic debridement was performed, antifungal treatment was started immediately, and infection was controlled following strict blood sugar control. The widespread use of steroids, and uncontrolled diabetes, are major risk factors that make patients susceptible to mucormycosis. In patients with COVID-19, physicians should be cautious of the possibility of invasive fungal infection. In addition to debridement, an active interdisciplinary approach can help reduce mortality.

Keywords

Corticosteroid , COVID-19 , diabetes , mucormycosis , rhinosinusitis

References

• Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5-264.e8.
• Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:105957.
• Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. 2021;64(8):798-808.
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12): e405-e421.
• Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020;30(2): 100971.
• Ardi P, Daie-Ghazvini R, Hashemi SJ, et al. Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug­ susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation. Microb Pathog. 2020;147:104382.
• Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43.
• Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-425.
• Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract. 2018;139:203-220.
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2): 120-128.
• Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349-2359.